title: Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix.
abstract: A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (∼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.
authors.affiliation: Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts 02115, United States.
authors.forename: Mathumai
authors.initials: M
authors.lastname: Kanapathipillai
authors.forename: Akiko
authors.initials: A
authors.lastname: Mammoto
authors.forename: Tadanori
authors.initials: T
authors.lastname: Mammoto
authors.forename: Joo H
authors.initials: JH
authors.lastname: Kang
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Jiang
authors.forename: Kaustabh
authors.initials: K
authors.lastname: Ghosh
authors.forename: Netanel
authors.initials: N
authors.lastname: Korin
authors.forename: Ashley
authors.initials: A
authors.lastname: Gibbs
authors.forename: Robert
authors.initials: R
authors.lastname: Mannix
authors.forename: Donald E
authors.initials: DE
authors.lastname: Ingber
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D005109:Extracellular Matrix / Q000187:drug effects*; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology*; D051379:Mice; D053769:Nanocapsules / Q000008:administration & dosage*; D008249:Protein-Lysine 6-Oxidase / Q000008:administration & dosage*
chemical_list: D053769:Nanocapsules; D008249:Protein-Lysine 6-Oxidase